Research programme: phosphodiesterase IV inhibitors - Dainippon Sumitomo Pharma

Drug Profile

Research programme: phosphodiesterase IV inhibitors - Dainippon Sumitomo Pharma

Alternative Names: OS-0217

Latest Information Update: 08 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Pyridines
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 08 Feb 2008 Discontinued - Preclinical for Asthma in Japan (PO)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 09 Sep 2004 Preclinical trials in Asthma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top